These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19221151)

  • 1. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.
    Choi YH; Ahn JH; Kim SB; Jung KH; Gong GY; Kim MJ; Son BH; Ahn SH; Kim WK
    Ann Oncol; 2009 Aug; 20(8):1337-43. PubMed ID: 19221151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
    Wu Y; Mohamed H; Chillar R; Ali I; Clayton S; Slamon D; Vadgama JV
    Breast Cancer Res; 2008; 10(1):R3. PubMed ID: 18184439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer.
    Cao W; Zhang B; Li J; Liu Y; Liu Z; Sun B
    Pathology; 2011 Dec; 43(7):713-8. PubMed ID: 22081131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis.
    Emi Y; Kitamura K; Shikada Y; Kakeji Y; Takahashi I; Tsutsui S
    Surgery; 2002 Jan; 131(1 Suppl):S217-21. PubMed ID: 11821814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer.
    Wang J; Xu B; Yuan P; Li Q; Zhang P; Cai R; Ma F; Fan Y; Luo Y
    Int J Biol Markers; 2014 Sep; 29(3):e187-92. PubMed ID: 25041784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
    Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
    Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
    Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
    Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival.
    Vasconcelos I; Hussainzada A; Berger S; Fietze E; Linke J; Siedentopf F; Schoenegg W
    Breast; 2016 Oct; 29():181-5. PubMed ID: 27544822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
    Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
    J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
    Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
    Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.
    Schneeweiss A; Goerner R; Hensel MA; Lauschner I; Sinn P; Kaul S; Egerer G; Beldermann F; Geberth M; Solomayer E; Grischke EM; Haas R; Ho AD; Bastert G
    Biol Blood Marrow Transplant; 2001; 7(6):332-42. PubMed ID: 11464976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a Meta-analysis].
    Guo H; Wei B; Zhang HY; Liu GJ; Bu H; Lang ZQ; Tang X; Dai QQ; Chen HJ; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):140-6. PubMed ID: 15938823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.